Live Feeds
● LIVE Updated 23h ago · 22 sources tracked

AbbVie’s biggest deal since 2019 could land soon

AbbVie announced on Monday it will buy Apogee Therapeutics for $10.9 billion in cash. This acquisition is the company's largest since 2019. The deal provides AbbVie with long-acting immunology and inflammatory disease drug candidates, including an experimental eczema treatment.

RSS Source map (20)

What changed

AbbVie officially announced the $10.9 billion acquisition of Apogee Therapeutics.

Live updates

  1. AbbVie to Acquire Apogee Therapeutics for $10.9 Billion

    AbbVie announced on Monday it will buy Apogee Therapeutics for $10.9 billion in cash. This acquisition is the company's largest since 2019. The deal provides AbbVie with long-acting immunology and inflammatory disease drug candidates, including an experimental eczema treatment.

    What's confirmed:

    • AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion.
    • The deal is AbbVie's largest acquisition in more than five years.
    • The acquisition includes long-acting immunology and inflammatory disease drug candidates.
    • The deal includes an experimental eczema drug.

    Still unconfirmed:

    • The purchase price represents a roughly 60% premium to Apogee's closing share price on June 18.
    • A separate pharmaceutical deal worth up to $20 billion may be looming over the sector.
    confidence 95%